Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer
This is a randomized controlled study to evaluate the efficacy and safety of toripalimab plus capecitabine as postoperative adjuvant therapy for patients with resectable advanced extrahepatic biliary tract cancer.
Gallbladder Cancer|Hilar Cholangiocarcinoma|Distal Cholangiocarcinoma
DRUG: Capecitabine|DRUG: Toripalimab
1-year recurrence-free survival rate, 1 year
1-year OS, 1 year|2-year OS, 2-year|Occurrence of adverse reactions, 1 year
This is a randomized controlled study to evaluate the efficacy and safety of toripalimab plus capecitabine as postoperative adjuvant therapy for patients with resectable advanced extrahepatic biliary tract cancer.